Josephine Harrington, MD
@jlharrington_md
Clinician and trialist @CUAnschutz and @CPCresearch. Prev. @Dukecardiology @DCRI @UTSWIM. Interested in HF, obesity, biomarkers and CVOTs. Tweets my own.
ID: 1436066050135703556
09-09-2021 20:36:51
225 Tweet
535 Followers
322 Following
A critical analysis of the data for vericiguat as a potential 5th pillar in HFrEF (link.springer.com/article/10.100…) noting ongoing evidence gaps. More to come with VICTOR. Congrats AE Savina Nodari #HREV. Steve Greene Josephine Harrington, MD Shahzeb Khan
Really excited to get this out there with Ankeet S. Bhatt, MD, MBA led by Ozan Unlu - don’t miss an opportunity to optimize #GDMT for 🫀failure! Muthu Vaduganathan Steve Greene @KPHeartDoc
It was a pleasure to collaborate with Josephine Harrington, MD and Stormi Gale for a Circ: Heart Failure review of "Anti-#Obesity Medications in Patients with #HF". ahajournals.org/doi/10.1161/CI…. The new multi-disciplinary Metabolic HF Clinic Cleveland Clinic Heart, Vascular & Thoracic is ramping up quickly with these protocols.
The pericardium modulates cardiac performance in #HFpEF. Pericardial constraint raises filling pressures in pts w/ obesity, atrial myopathy, RV dysfunction, & TR. #Pericardiotomy as a new treatment option. #HREV (link.springer.com/article/10.100…) Josephine Harrington, MD Marat Fudim, MD MHS Jan Biegus
HFpEF is a high inflammatory state—and GLP-1 RAs like semaglutide could be the game-changer. The STEP-HFpEF trials show real promise: weight loss and improved QoL. Will this become SoC for obese HFpEF? (link.springer.com/article/10.100…) #HREV Marco Metra Mikhail Kosiborod Josephine Harrington, MD
Such an honor to be joining this incredible group of women CVCT - CardioVascular Clinical Trialists this year!
Incredible work by 🌟 fellow Mark Kittipibul MD and luminary Carolyn Lam on how AF and HFpEF interact and drive each other. Delighted to have be featuring this foundational review in our spotlight #HFRev issue on HFpEF: link.springer.com/collections/fd…
"Leptin: the 'chicken' in HFpEF, the 'egg' in HFrEF. 🐔🥚 In HFpEF, it drives disease via inflammation, fibrosis, & diastolic dysfunction. In HFrEF, it's a secondary response. Will targeting leptin in HFpEF may improve outcomes? (link.springer.com/article/10.100…) #HREV Josephine Harrington, MD
🔥 #CONFIDENCE closed out & selected as LBCT to headline #ERA25, led by #ProfRajivAgarwal Largest RCT to test combination #SGLT2i empagliflozin & #nsMRA finerenone Will 1+1 = 2? Baseline: academic.oup.com/ndt/advance-ar… Design: academic.oup.com/ndt/article/38… See you in Vienna 🇦🇹 ERA - European Renal Association
HFpEF is a growing public health burden with few proven therapies. Exercise training improves function, with modalities ranging from moderate-intensity to multi-modal and emerging options like IMT and FES. (link.springer.com/article/10.100…). Anthony Peters Josephine Harrington, MD
Current evidence and future perspectives in HFpEF therapy. #HREV Josephine Harrington, MD Caio de Assis Moura Tavares Andrew P. Ambrosy, MD, MPH orlyvardeny Andrew J Sauer MD Marc Bonaca MD MPH CPC Clinical Research link.springer.com/article/10.100…
#CONFIDENCE results: now explore HF #CONFIRMATION-HF, we enrolled 12th patient Saint Luke's Mid America Heart Institute today! Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF) | ClinicalTrials.gov
Obesity drives a unique, early-onset form of HFpEF—often underdiagnosed. Yet, no guidelines recommend screening. This review outlines why systematic screening in obesity is overdue and proposes a tailored approach (link.springer.com/article/10.100…). #HREV Josephine Harrington, MD Marat Fudim, MD MHS
